Italy· 019954015
ALDOMET*30 cpr rivestite 500 mg
A methyldopa (levorotatory) product containing metildopa, registered in Italy by H.A.C.PHARMA, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Methyldopa (levorotatory) is registered in 10 of 19 countries.
Countries holding a registration under ATC C02AB01 (methyldopa (levorotatory)), each read from that country’s own register.
- This record: Italy
- 7 of them publish a price we can compare per daily dose
Methyldopa (levorotatory) · ATC C02AB01
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of methyldopa (levorotatory) costs, country by country.
Normalised to the WHO defined daily dose (1 g), so markets compare like for like.
- Italy: $0.42 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Methyldopa (levorotatory) · price per daily dose (1 g)
USD · FX 28 Sept 2026
- IT Italy$0.42
The record
At a glance
- Active substance
- Metildopa
- Manufacturer
- H.A.C.PHARMA
- Country
- Italy (IT)
- ATC code
- C02AB01
- ATC class
- Methyldopa (levorotatory)
- Defined daily dose
- 1 g, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic019954015ALDOMET*30 cpr rivestite 500 mgEUR 5.52
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
182 interactions on record for methyldopa (levorotatory).
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Methyldopa (levorotatory) · interactions on record
182 records
- 8 severe
- 95 moderate
- 10 minor
- 69 info
Most severe, free to view
- ProcarbazineL01XB01severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- OzanimodL04AA38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C02AB01
Methyldopa (levorotatory), as other registers publish it.
- FinlandAdopalOrion Corporation Orion Pharma
- FinlandAdopalPharmacal Oy Ab
- FinlandAdopalOrion Corporation Orion Pharma
- FinlandAdopalPharmacal Oy Ab
- NorwayAldometAspen Global Health and Development
- FinlandAldometMerck Sharp & Dohme B.V.
- FinlandAldometMerck Sharp & Dohme B.V.
- FinlandAldometMerck Sharp & Dohme B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5e9b3d83-18cf-4822-93f0-6f3882f56bff GET /v1/drugs/5e9b3d83-18cf-4822-93f0-6f3882f56bff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 5.52,
"source": "aifa",
"currency": "EUR",
"strength": "METILDOPA 500MG 30 UNITA' USO ORALE",
"substance": "Metildopa",
"equivalence_group": "ONA",
"transparency_flag": null
}See everything about methyldopa (levorotatory).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.